Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment

Sam Slutsky, an analyst from LifeSci Capital, has initiated a new Buy rating on Eupraxia Pharmaceuticals (EPRX).

Sam Slutsky’s rating is based on Eupraxia Pharmaceuticals’ promising development of EP-104GI, a long-acting, controlled-release formulation of fluticasone propionate for treating eosinophilic esophagitis (EoE). This formulation is designed to be delivered via submucosal injections into the esophageal wall, potentially offering a more effective and less frequent dosing schedule compared to current off-label treatments. The Phase 1b/2a data indicates that EP-104GI maintains systemic exposure within safe levels while targeting a broader area of the esophagus.
Furthermore, the market potential for EoE treatments is significant, with an estimated 500,000 patients in the US alone. Conversations with key opinion leaders suggest that EP-104GI could become a critical treatment option, with projected peak global sales reaching $1.52 billion. The anticipated topline data from the ongoing Phase 2b study in the second half of 2026 could further bolster the drug’s prospects, supporting the Buy rating given by Slutsky.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.